Majem, MargaritaCobo, ManuelIsla, DoloresMarquez-Medina, DiegoRodriguez-Abreu, DelvysCasal-Rubio, JoaquínBueno, Teresa MoranBernabé-Caro, ReyesParente, Diego PérezRuiz-Gracia, PedroArroyo, Marta MarinaPaz-Ares, Luis2023-02-092023-02-092021-03-262077-0383http://hdl.handle.net/10668/17524Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to evaluate the efficacy of first-line anti-PD-(L)1 monotherapy in advanced NSCLC patients with high PD-L1 expression (≥50%) compared to platinum-based chemotherapy. We also evaluated efficacy outcomes according to tumor mutational burden (TMB). To that end, we conducted a systematic review. Six clinical trials with 2111 patients were included. In head-to-head comparisons, immunotherapy showed a significant improvement in progression-free survival (PFS: HRpooled = 0.69, 95% CI: 0.52-0.90, p = 0.007), overall survival (OS: HRpooled = 0.69, 95% CI: 0.61-0.78; penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/PD-(L)1 inhibitorsefficacyfirst-line treatmentimmunotherapynetwork meta-analysisnon-small cell lung cancerresearch article33810441open access10.3390/jcm10071365PMC8036854https://www.mdpi.com/2077-0383/10/7/1365/pdf?version=1617937091https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036854/pdf